Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03972137 · ClinicalTrials.gov registry record · Phase 2
Heart Rate Variability Biofeedback for Smoking Cessation
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03972137 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 10 participants.
The verdict
NCT03972137, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Open trial of heart rate variability biofeedback as an adjunct to individualized smoking cessation counseling (SCT) plus transdermal nicotine replacement patch (NRT) in smokers with elevated emotional distress.
Interventions
- DRUG Transdermal Nicotine patch
- BEHAVIORAL Cognitive-Behavioral Smoking Cessation
- BEHAVIORAL Heart Rate Variability Biofeedback (HRVB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2020-02-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03972137
The ClinicalTrials.gov registry entry for NCT03972137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Transdermal Nicotine patch is the first listed.
NCT03972137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03972137 about?
NCT03972137 is a clinical study titled "Heart Rate Variability Biofeedback for Smoking Cessation". Open trial of heart rate variability biofeedback as an adjunct to individualized smoking cessation counseling (SCT) plus transdermal nicotine replacement patch (NRT) in smokers with elevated emotional distress.
What is the current status of trial NCT03972137?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-04-24. Estimated completion is 2020-02-20.
What interventions are being tested in trial NCT03972137?
The interventions under investigation include: Transdermal Nicotine patch (DRUG), Cognitive-Behavioral Smoking Cessation (BEHAVIORAL), Heart Rate Variability Biofeedback (HRVB) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03972137?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.